DEPARTMENTS
img_201710-FRANK
RISKY BUSINESS
Ironing Out Welding Carcinogenicity?
In April 2017, IARC reclassified welding fumes as “known” to be carcinogenic to humans (group 1) from the previous classification as “possibly” carcinogenic in 1990 (group 2B). The full monograph 118 will probably be available next year. For now, you can read a summary in The Lancet.

Welding fume exposure is widespread and diverse. The Bureau of Labor Statistics estimates there are 400,000 welders in the U.S., and there are likely more jobs where workers do some welding. So IARC’s finding expands our view of the extent of exposures that pose a disease risk, both to bystanders at work and for the environment where the welding fume components are present. The working group noted that after exhaustive literature review,
[m]ost studies, including more than 20 case-control studies and nearly 30 occupational or population-based cohort studies, reported increased risks of lung cancer in welders or other workers exposed to welding fumes. Exposure-response associations with indices of longer or greater cumulative exposure to welding fumes were also reported in several studies, some of which were large, high-quality studies.
The monograph also noted consistent increases in kidney cancer, but opined that other non-fume exposures in the welding environment could not be ruled out as causes. Summaries of this literature note that the excess of lung cancer in these studies of welders was in the range of 25 percent, which translates to about 1 percent risk (10 in 1,000) of lung cancer at whatever summary measure of exposure can be derived from this body of studies, compared to the benchmark of 1 in 1,000 the Supreme Court defined as “significant” risk.
This calculation shows that any agent clearly carcinogenic in a study in people is a high priority risk. Practitioners require an occupational exposure limit (OEL) to evaluate the riskiness and need for additional controls in a specific environment. We should also consider how this new authoritative conclusion impacts our view of the protection conferred by OELs promulgated before this finding. COMPARING PROCESSES Carcinogen classification communicates risk, stratified by the certainty of the direct observations of the toxic potential of an agent, mixture, or exposure circumstance. The IARC monograph program, the National Toxicology Program's Report on Carcinogens, and the California Proposition 65 list are comprehensive resources. The IARC classifications, “known” (group 1), “probable” (group 2A), and “possible” (group 2B), contrast with the NTP classifications of “known” or “reasonably anticipated” (combining IARC 2A and 2B). The NTP terms are set by federal legislation. Most of the IARC 2B carcinogens got there via “sufficient” evidence in laboratory studies combined with “inadequate” evidence (usually no studies) in people. IARC 2A usually means there is “limited” evidence in people. IARC also lists about 500 agents as “not classifiable”; for many of these there is “limited” evidence in laboratory studies and no data in people. Personally, I think “reasonably anticipated” communicates more certainty of risk than “possibly.” NTP does not address “exposure circumstances,” such as welding.
The priorities for IARC reviews are set by a panel of scientific experts (PDF). The IARC process consists of working groups: scientists in the field without conflicts of interest, who review publications, draft the monograph, meet face to face over the course of 10 days to revise it, and vote on classification. Experts with conflicts may also be invited and can contribute to the discussion but have no vote.

The priorities for listing in the Report on Carcinogens are set by NTP staff and by petition. Typically, the ROC lags classifications by IARC, and may not include all the agents classified by IARC. The NTP review process consists of staff (who are scientists) compiling literature and proposing a classification, followed by external peer review by independent scientists and a public meeting at which stakeholders can comment. Following the external peer review, the listing is voted by agency heads and reviewed by the office of the secretary of the Department of Health and Human Services (which is subject to lobbying). The political review explains why the “annual” report on carcinogens became a report without an interval. In my view the IARC process is stronger in epidemiology than NTP’s, and usually precedes consideration by NTP. EPA will also assess carcinogenic potential under its IRIS program, as will ACGIH, but these classifications have little direct relationship to OEL recommendations.
IARC’s assessment of laboratory evidence for carcinogenicity is straightforward. Usually it’s considered “sufficient” if two experiments observe increased tumors. Laboratory evidence was lacking for welding fume. Sufficient evidence in people requires multiple studies, although usually less than the 50 welding fume studies noted in the IARC summary quoted above. The 1990 Monograph 49 on welding fume cited nine cohort studies (two were considered null) and 12 case control studies (again, two considered null). Those data were determined to be “limited.” A detailed comparison of the new evidence that carried welding fume from “possibly” to “known” will have to wait for the full Monograph 118 to be published. This evolution took 18 years, and maybe 30 major studies, which is 18 years’ delay in taking the original evidence into account.
FRANK MIRER, PhD, CIH, is a professor in the CUNY School of Public Health in New York. He can be reached at (212) 396-7782 or via email.
TOC
NEWSWATCH
COMMUNITY
the Synergist
DEPARTMENTS
TOC
NEWSWATCH
COMMUNITY
the Synergist
DEPARTMENTS